Insider Selling: Progyny (NASDAQ:PGNY) COO Sells 9,578 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) COO Melissa Cummings sold 9,578 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $25.00, for a total value of $239,450.00. Following the completion of the transaction, the chief operating officer owned 73,371 shares in the company, valued at approximately $1,834,275. This trade represents a 11.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Trading Down 3.7%

Shares of Progyny stock traded down $0.95 during trading hours on Thursday, reaching $24.69. The stock had a trading volume of 1,424,301 shares, compared to its average volume of 1,560,195. The firm has a 50 day simple moving average of $18.78 and a two-hundred day simple moving average of $21.97. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 32.06, a P/E/G ratio of 1.31 and a beta of 0.91. Progyny, Inc. has a 1 year low of $16.10 and a 1 year high of $28.75.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The company had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.47 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The company’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same period last year, the business posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Sell-side analysts forecast that Progyny, Inc. will post 1.12 EPS for the current year.

Institutional Investors Weigh In On Progyny

Hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Progyny during the 4th quarter valued at about $25,000. Federated Hermes Inc. grew its stake in Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after purchasing an additional 819 shares in the last quarter. Hantz Financial Services Inc. grew its stake in Progyny by 79.4% during the 4th quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after purchasing an additional 742 shares in the last quarter. Covestor Ltd grew its stake in Progyny by 164.9% during the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock valued at $56,000 after purchasing an additional 1,624 shares in the last quarter. Finally, Quarry LP grew its stake in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after purchasing an additional 3,427 shares in the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on PGNY shares. BTIG Research cut their price objective on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. KeyCorp dropped their target price on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Zacks Research upgraded Progyny from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Truist Financial raised their target price on Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, May 11th. Finally, Barclays raised their target price on Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.55.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.